Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for the treatment of treating a neoplastic disease or disorder having cells expressing CD40 in a mammal, comprising:

administering to the mammal an effective amount of a combination consisting essentially of:

   a. a CD20 specific binding agent; and
   
   b. an agent that arrests the growth of or causes deletion of cells expressing CD40, wherein the agent consists of a CD40 specific binding agent that stimulates CD40 and a CD20 specific binding agent,

wherein said combination is sufficient for therapeutically effective treatment of said inhibits the neoplastic disease or disorder in said mammal.

2. (Original) The method according to claim 1 wherein the neoplastic disease or disorder is a hematological malignancy.

3. (Original) The method according to claim 1 wherein the neoplastic disease or disorder is a solid tumor.

4. (Original) The method according to claim 2 wherein the malignancy is a lymphoma.

5. (Original) The method according to claim 4 wherein the lymphoma is a non-hodgkins type lymphoma.

6. (Original) The method according to claim 2 wherein the malignancy is a myeloma.
7. (Original) The method according to claim 6 wherein the myeloma is a multiple myeloma.

8. (Original) The method according to claim 2 wherein the malignancy is a leukemia.

9. (Previously Presented) The method according to claim 1 wherein the CD40 specific binding agent is an antibody.

10. (Original) The method according to claim 9 wherein the antibody is a monoclonal antibody.

11. (Previously Presented) The method according to claim 10 wherein the monoclonal antibody is the monoclonal antibody secreted by the hybridoma having ATCC® Accession No. PTA-110.

12. (Cancelled).

13. (Previously Presented) The method according to claim 1 wherein the CD20 binding agent is an antibody.

14. (Currently Amended) The method according to claim 13 wherein the antibody CD20 binding agent is a monoclonal antibody.

15. (Currently Amended) The method according to claim 14 wherein the monoclonal antibody is the monoclonal a chimeric antibody produced by the transfectedoma having ATCC® deposit number 69119.

16. (Previously Presented) The method according to claim 9 wherein the CD20 binding agent is an antibody.

17. (Currently Amended) The method according to claim 16 wherein the antibody CD20 specific agent is a monoclonal antibody.

18. (Currently Amended) The method according to claim 17 wherein the antibody CD20 binding agent is an antibody produced by the transfectedoma having ATCC® deposit number 69119.
19. (Withdrawn - Amended) A pharmaceutical composition comprising an amount effective for the treatment of treating a neoplastic disease or disorder characterized by cells expressing CD40, consisting essentially of: (a) an agent that arrests the growth of or causes deletion of cells expressing CD40 wherein the agent consists of a CD40 specific binding agent that stimulates CD40; (b) a CD20 specific binding agent; and (c) a pharmaceutically acceptable carrier.

20-31. (Cancelled).

32. (Currently Amended) The method of claim 1, wherein said CD40 specific binding agent and said CD20 specific agent are administered simultaneously.

33. (Currently Amended) The method of claim 1, wherein said CD40 specific binding agent and said CD20 specific agent are administered separately sequentially.

34. (New) The method of claim 1, wherein the CD40 specific binding agent is a chimeric antibody.

35. (New) The method of claim 1, wherein the CD40 specific binding agent is a humanized antibody.

36. (New) The method of claim 1, wherein the CD20 specific binding agent is a humanized antibody.

37. (New) The method of claim 1, wherein the CD40 specific binding agent is a humanized antibody derived from SGN-14 (ATCC® Accession No. PTA-110).

38. (New) The method of claim 1, wherein the CD40 specific binding agent is a chimeric antibody derived from SGN-14 (ATCC® Accession No. PTA-110).

39. (New) The method of claim 1, wherein the CD20 specific binding agent is a humanized antibody derived from rituximab (ATCC® Accession No. 69119).

40. (New) The method of claim 1, further comprising administering a cytotoxic or chemotherapeutic agent, simultaneously or sequentially with said combination.
41. (New) The method of claim 1, further comprising administering one or more of a maytansine, a calicheamicin, or a trichothene, simultaneously or sequentially with said combination.

42. (New) The method of claim 1, further comprising administering Gemzar™, simultaneously or sequentially with said combination.

43. (New) The method of claim 1, wherein the CD40 specific binding agent, the CD20 specific binding agent, or both, is conjugated to a cytotoxic agent.

44. (New) The method claim 34, wherein the cytotoxic agent comprises a radioactive isotope, a chemotherapeutic agent, or a toxin.

45. (New) The method of claim 1, wherein the CD40 specific binding agent, the CD20 specific binding agent, or both, is conjugated to a prodrug-activating enzyme which converts a prodrug to an active anti-cancer drug.

46. (New) The method of claim 9, wherein the antibody is an antibody fragment.

47. (New) The method of claim 37, wherein the antibody fragment is a Fab, Fab', F(ab')2, Fv, diabody, linear antibody, sFv, or a multispecific antibody formed from antibody fragments.

48. (New) The method of claim 13, wherein the antibody is an antibody fragment.

49. (New) The method of claim 39, wherein the antibody fragment is a Fab, Fab', F(ab')2, Fv, diabody, linear antibody, sFv, or a multispecific antibody formed from antibody fragments.